DR67 DataRelease
Release Date: August 2026
New Studies: 3
Updated Studies: 2
New Studies
| SDY3462: Enrichment of Vd1/3 T cells in tuberculosis | ||||||||||||||||
| Status: | New | |||||||||||||||
| Description: | In this study, we used single-cell RNA sequencing to provide a high-resolution characterization of CD4-CD8- ?? T cells in peripheral blood across healthy Mtb-non-sensitized, healthy Mtb-sensitized, and TB disease pre-/post-treatment cohorts. We found upregulation of an activated and cytotoxic gene signature in ?? T cells of TB disease compared to both healthy cohorts. Strikingly, these differences persisted through one year following diagnosis of TB disease (corresponding to six months after completion of anti-TB therapy). We found that these transcriptomic differences were largely mediated by an NK-like cytotoxic Vd1 and Vd3 subset that was enriched in TB disease, with a unique Vd3 TCR gene usage. Our findings suggest long-lasting changes in the CD4-CD8- ?? T cell compartment and highlight Vd3 cells, a previously underappreciated ?? T cell subset, as potentially important in TB. | |||||||||||||||
| Program/Contract: |
|
|||||||||||||||
| DOI: | 10.21430/M30OG74D7C | |||||||||||||||
| Subjects: | 126 | |||||||||||||||
| Study PI, contact: |
|
|||||||||||||||
| Publications: |
|
|||||||||||||||
| Resources: |
|
|||||||||||||||
| Assays: | None | |||||||||||||||
| Clinical Assessments: | None | |||||||||||||||
| Release Notes: |
|
|||||||||||||||
| SDY3499: Care of Naive Rhesus Macaques | |||||||
| Status: | New | ||||||
| Description: | This study includes naïve rhesus macaques maintained in an AAALAC-accredited animal facility and used as non-experimental control animals for related nonhuman primate studies. Animals were age- and sex-matched to experimental cohorts and were not irradiated or otherwise treated. The purpose of including these animals was to provide reference data for normal blood values, evaluate assay stability over the course of a study, and establish histopathologic findings in tissues from unirradiated animals collected at necropsy. These control data supported comparison with studies evaluating radiation-induced bone marrow and gastrointestinal aplasia and lung injury in rhesus macaques. Data from these studies were used in SDY1854, SDY1997, SDY2002, and SDY2058. Keywords: rhesus macaques, Macaca mulatta, radiation, natural history, radiation sickness, hematopoietic, gastrointestinal, lung, hematology, metabolomics, histology, RNCP | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M356WSOIOE | ||||||
| Subjects: | 11 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3726: NASIR-HCC JITC 2026 | |||||||
| Status: | New | ||||||
| Description: | Background & Aims: Selective internal radiation therapy (SIRT) combined with immune checkpoint inhibitors (ICI) has shown encouraging clinical activity against hepatocellular carcinoma (HCC), but prediction of clinical benefit and mechanisms of resistance remain elusive. Methods: In the NASIR-HCC phase II trial, unresectable HCC patients received SIRT plus nivolumab. Baseline tumor biopsies were profiled using bulk RNA sequencing, multiplex immunofluorescence, and spatial proteomics to investigate immune and stromal features associated with clinical benefit. Results: Contrary to ICI-only settings, pre-existing immune infiltrates and inflammatory signatures did not predict clinical benefit from SIRT plus nivolumab. Patients without benefit exhibited enrichment in fibroblast-related programs, including epithelial-to-mesenchymal transition and extracellular matrix remodeling, alongside elevated fibroblast activation protein expression. Spatial proteomics revealed accumulation of activated lymphocytes within fibrotic stromal regions of non-responders, suggesting the presence of an immune-rich but ineffective infiltrate due to the stromal barrier. Transcriptomic integration with single-cell datasets highlighted the associatiion of oncofetal cancer-associated fibroblasts (CAFs), particularly periostin (POSTN)-expressing, to resistance, whereas patients with benefit showed enrichment in oxidative phosphorylation pathways. Conclusions: The efficacy of SIRT plus nivolumab in HCC is not associated to baseline T-cell infiltration but to the presence of oncofetal POSTN+ CAF in the stroma. Targeting stromal remodeling and fibroblast reprogramming may further enhance the efficacy of SIRT plus ICIs in HCC. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3OC29QJ8K | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
Updated Studies
| SDY3302: Innaptives | |||||||
| Status: | Updated | ||||||
| Description: | The panel described here was designed to quantify populations of cells that may influence protection against Mycobacterium tuberculosis (Mtb) infection in naïve control animals enrolled in pre-clinical NHP vaccine studies. This panel may be used to identify and assess unconventional T cell populations related to other disease models, such as cancer and HIV. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3GE6X8EP6 | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3689: GI-ARS Efficacy Study in Rhesus Macaques after Partial Body Irradiation (PBI/BM5) - Control Animals | |||||||
| Status: | Updated | ||||||
| Description: | Prior to irradiation, NHP were randomized to either a control (n = 15) or treated (n = 15) cohort. On Study Day (SD) 0, each NHP was sedated, restrained, and transported to the LINAC facility. They were then placed on the LINAC treatment table and positioned within the lighted radiation field in such a way that the whole body was contained within the field, with the exception of the tibiae, ankles, and feet (i.e., the field terminated at the inferior edge of the patella). After positioning, the NHPs were exposed to six (6) megavolt (MV) photons delivered at a dose rate of approximately 0.80 Gy/min, resulting in PBI/BM5 to a targeted dose of 12.0 Gy. Following irradiation, NHP were administered six (6) SC injections of either TA or CA (10 mM histidine buffer in water at 0.1 ml/kg) at 24 ± 2 hour intervals from the time of irradiation. All animals were monitored for complete blood count (CBC), plasma levels of blood urea nitrogen (BUN) and creatinine (Cr), body weight (BW), rectal body temperature (RBT), stool consistency, and clinical hydration status through the end of the in-life phase. Animals received medical management consisting of intravenous (IV) fluids, antibiotics, analgesics, antidiarrheals, antiemetics, blood transfusions, supplemental nutrition, and other support as required. rhesus macaques, Macaca mulatta, radiation, natural history, radiation sickness, gastrointestinal, hematology, histology, cytokines, RNCP Animals were euthanized according to a set of criteria based on clinical signs including activity level, weight loss, and responsiveness to antidiarrheal treatment, or between SD31 and SD35 if criteria were not met during the in-life phase. Survival was analyzed at 15 and 30 days postirradiation. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3WHI3TIET | ||||||
| Subjects: | 15 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||